Just the Start for
We have developed a range of current products with FDA approval for clinical trials, aiming to make drug administration easier and more efficient.
The clinical trial for HypoSpray Insulin Delivery found that the HypoSpray Insulin Delivery consistently achieved better glucose control than the traditional method of insulin injection.
The clinical trial demonstrated that the HypoSpray Insulin Delivery system could provide more accurate and predictable glucose control, with fewer adverse reactions than traditional insulin injection. The results also suggested that by taking advantage of the body's natural feedback loops and leveling tendencies, patients could better manage their diabetes.
Overall, the clinical trial for HypoSpray Insulin Delivery provided promising results for patients. The results suggest that using this delivery system could lead to improved glucose control and better overall management of the condition.
HypoSpray Pharma's clinical program for Epinephrine includes a clinical pharmacology study to assess the safety, tolerability, and pharmacokinetics of HypoSpray® Epinephrine compared to intravenous epinephrine.
This study is designed to provide data to support a New Drug Application (NDA) submission to the FDA. Additionally, HypoSpray Pharma is conducting a clinical trial to assess the efficacy of HypoSpray® Epinephrine in treating anaphylaxis in patients who are allergic to food or insect stings. This trial is designed to support the NDA submission. The data collected from both studies will be used to support the safety and efficacy of HypoSpray® Epinephrine for the treatment of anaphylaxis.
Currently enrolling for dosing and transference studies for its first product, Testagen® spray-on Testosterone. The testosterone market exceeds $2 billion annually, of which a single gel product represents more than 50%—however, this gel product can be transferred on contact with another person up to 24 hours after dosing. In contrast, HYPOSPRAY Pharma’s Testagen® product speeds absorption and reduces transference risk to 20 minutes or less.
Spray-on testosterone offers a massive advantage over the incumbent gel product with dramatic lifestyle improvement for patients who are currently unable to dress quickly, exercise, shower, or have intimate relations for up to eight hours after application to avoid washing off or transferring the gel to another person.
DicloMist® Diclofenac Sodium (NSAID)
HYPOSPRAY Pharma is developing transdermal variants of Diclofenac, Ibuprofen and Acetaminophen, which will enable significantly lower dosages to be administered without loss of pain relief, while reducing pain medication side effects such as nausea, improving safety characteristics through mitigation of liver toxicity due to lowered doses, and easier administration to major sub-segments such as pediatrics.